Bone tissue engineering using foetal cell therapy

Swiss Medical Weekly

Volumn 137, Issue SUPPL. 155, 2007, Pages

  Pioletti, Dominique P ^a   Montjovent, Marc Olivier ^a   Zambelli, Pierre Yves ^b   Applegate, Lee ^c  

^a EPFL   (Switzerland)

^b Hopital Orthopedique de la Suisse Romande   (Switzerland)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Cell bank; Cell therapy; Foetal

Indexed keywords

BONE MORPHOGENETIC PROTEIN; RECOMBINANT PROTEIN;

BONE MARROW CELL; BONE TISSUE; CELL CULTURE; CELL DIFFERENTIATION; CELL THERAPY; CLINICAL TRIAL; DEGENERATIVE DISEASE; DNA MODIFICATION; FETUS CELL; GENE EXPRESSION; HUMAN; HUNTINGTON CHOREA; IMMUNE RESPONSE; IN VITRO STUDY; MESENCHYMAL STEM CELL; NONHUMAN; OSTEOBLAST; PARKINSON DISEASE; SHORT SURVEY; SPINAL CORD INJURY; STROKE; TISSUE ENGINEERING;

EID: 34249338718     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (31)

1. Shea LD, Wang D, Franceschi RT, Mooney DJ. Engineered bone development from a pre-osteoblast cell line on three-dimensional scaffolds. Tissue Eng 2000;6:605-17.
2. Caplan AI, Goldberg VM. Principles of tissue engineered regeneration of skeletal tissues. Clin Orthop 1999:S12-16.
3. Bruder SP, Fox BS. Tissue engineering of bone. Cell based strategies. Clin Orthop 1999:S68-83.
4. Weissman IL. Translating stem and progenitor cell biology to the clinic: Barriers and opportunities. Science 2000;287:1442-6.
5. Javazon EH, Beggs KJ, Flake AW. Mesenchymal stem cells: Paradoxes of passaging. Exp Hematol 2004;32:414-25.
6. Connolly J, Guse R, Lippiello L, Dehne R. Development of an osteogenic bone-marrow preparation. J Bone Joint Surg Am 1989;71:684-91.
7. Inoue K, Ohgushi H, Yoshikawa T, Okumura M, Sempuku T, Tamai S, et al. The effect of aging on bone formation in porous hydroxyapatite: Biochemical and histological analysis. J Bone Miner Res 1997;12:989-94.
8. Kahn A, Gibbons R, Perkins S, Gazit D. Age-related bone loss: A hypothesis and initial assessment in mice. Clin Orthop Relat Res 1995:69-75.
9. Mauney JR, Volloch V, Kaplan DL. Role of adult mesenchymal stem cells in bone tissue engineering applications: Current status and future prospects. Tissue Eng 2005;11:787-802.
10. Shi S, Gronthos S, Chen S, Reddi A, Counter CM, Robey PG, et al. Bone formation by human postnatal bone marrow stromal stem cells is enhanced by telomerase expression. Nat Biotechnol 2002;20:587-91.
11. Simonsen JL, Rosada C, Serakinci N, Justesen J, Stenderup K, Rattan SI, et al. Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells. Nat Biotechnol 2002;20:592-6.
12. Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, et al. Multilineage cells from human adipose tissue: Implications for cell-based therapies. Tissue Eng 2001;7:211-28.
13. Bosch P, Musgrave DS, Lee JY, Cummins J, Shuler T, Ghivizzani TC, et al. Osteoprogenitor cells within skeletal muscle. J Orthop Res 2000;18:933-44.
14. Whang PG, Lieberman JR. Clinical issues in the development of cellular systems for use as bone graft substitutes. In: Laurencin CT, ed. Bone graft substitutes. ASTM International 2003:142-63.
15. Kadiyala S, Young RG, Thiede MA, Bruder SP. Culture expanded canine mesenchymal stem cells possess osteochondrogenic potential in vivo and in vitro. Cell Transplant 1997;6:125-34.
16. Montjovent MO, Burri N, Mark S, Federici E, Scaletta C, Zambelli PY, et al. Fetal bone cells for tissue engineering. Bone 2004;35:1323-33.
17. Lauffenburger DA, Schaffer DV. The matrix delivers. Nat Med 1999;5:733-4.
18. Gazit D, Turgeman G, Kelley P, Wang E, Jalenak M, Zilberman Y, et al. Engineered pluripotent mesenchymal cells integrate and differentiate in regenerating bone: A novel cell-mediated gene therapy. J Gene Med 1999;1:121-33.
19. Kaviani A, Guleserian K, Perry TE, Jennings RW, Ziegler MM, Fauza DO. Fetal tissue engineering from amniotic fluid. J Am Coll Surg 2003;196:592-7.
20. Kadner A, Hoerstrup SP, Tracy J, Breymann C, Maurus CF, Melnitchouk S, et al. Human umbilical cord cells: A new cell source for cardiovascular tissue engineering. Ann Thorac Surg 2002;74:S1422-8.
21. Kaviani A, Perry TE, Barnes CM, Oh JT, Ziegler MM, Fishman SJ, et al. The placenta as a cell source in fetal tissue engineering. J Pediatr Surg 2002;37:995-9; discussion 995-9.
22. Mitka M. Amniotic cells show promise for fetal tissue engineering. JAMA 2001;286:2083.
23. Rosser AE, Dunnett SB. Neural transplantation in patients with huntington's disease. CNS Drugs 2003;17:853-67.
24. Clarkson ED. Fetal tissue transplantation for patients with parkinson's disease: A database of published clinical results. Drugs Aging 2001;18:773-85.
25. Freeman TB. From transplants to gene therapy for parkinson's disease. Exp Neurol 1997;144:47-50.
26. Savitz SI, Dinsmore JH, Wechsler LR, Rosenbaum DM, Caplan LR. Cell therapy for stroke. NeuroRx 2004;1:406-14.
27. Reier PJ. Cellular transplantation strategies for spinal cord injury and translational neurobiology. NeuroRx 2004;1:424-51.
28. Touraine JL, Roncarolo MG, Bacchetta R, Raudrant D, Rebaud A, Laplace S, et al. Fetal liver transplantation: Biology and clinical results. Bone Marrow Transplant 1993;11(Suppl 1):119-22.
29. Hohlfeld J, de Buys Roessingh A, Hirt-Burri N, Chaubert P, Gerber S, Scaletta C, et al. Tissue engineered fetal skin constructs for paediatric burns. Lancet 2005;366:840-2.
30. Park J, Ries J, Gelse K, Kloss F, von der Mark K, Wiltfang J, et al. Bone regeneration in critical size defects by cell-mediated bmp-2 gene transfer: A comparison of adenoviral vectors and liposomes. Gene Ther 2003;10:1089-98.
31. Verma IM, Somia N. Gene therapy: Promises, problems and prospects. Nature 1997;389:239-42.